Combined therapy of extensive genital endometriosis with aromatase inhibitors

Mariya Igorevna Yarmolinskaya; Arseniy Sergeyevich Molotkov; Anna Olegovna Durnova; Viktoriya Olegovna Polyakova; Igor Moiseyevich Kvetnoy; Vitaliy Fedorovich Bezhenar

doi:10.17816/JOWD62164-70

Journal of obstetrics and women's diseases ›› 2013, Vol. 62 ›› Issue (1) : 64 -70. DOI: 10.17816/JOWD62164-70

Articles

research-article

Combined therapy of extensive genital endometriosis with aromatase inhibitors

Author information +

History +

PDF

Abstract

The article represents our experience in evaluation of aromatase activity in endometriotic lesions. We revealed that the most important parameter in evaluating aromatase activity is the area of its expression. Increased activity of this enzyme in the foci of endometriosis was identified, which proved the prescription of aromatase inhibitors in postoperative period for 68 patients of reproductive age with genital endometriosis. It was shown that the combined therapy of endometriosis-aromatase inhibitors and progestagens (19-nortestosterone derivatives) is effective, safe and well tolerated way of treatment of the disease, but, undoubtedly, this scheme requires further research

Keywords

genital endometriosis / aromatase / immunohistochemical study / reduced ovarian reserve / aromatase inhibitors

Cite this article

Download citation ▾

Mariya Igorevna Yarmolinskaya, Arseniy Sergeyevich Molotkov, Anna Olegovna Durnova, Viktoriya Olegovna Polyakova, Igor Moiseyevich Kvetnoy, Vitaliy Fedorovich Bezhenar. Combined therapy of extensive genital endometriosis with aromatase inhibitors. Journal of obstetrics and women's diseases, 2013, 62(1): 64-70 DOI:10.17816/JOWD62164-70

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Значение экспрессии ароматазы в патогенезе наружного генитального эндометриоза / А. С. Молотков [и др.] // Молекулярная медицина. — 2012. — № 4. — С. 41–44.

[2]	Назаренко Т. А., Дмитриев Д. В. Ингибиторы ароматазы в репродуктивной медицине // Проблемы репродукции. — 2007. — Т. 13, № 1. — С. 14–20.

[3]	Новые патогенетические аспекты распространенного инфильтративного эндометриоза: теория и практика / Л. В. Адамян [и др.] // Проблемы репродукции. — 2010. — № 4. — С. 31–36.

[4]	Сонова М. М., Борзенкова И. П. Экспрессия ароматазы в патогенезе эндометриоза // ХХХ Юбилейная итоговая конференция молодых ученых: труды конференции. — М., 2008. — С. 313–315.

[5]	Ярмолинская М. И. Генитальный эндометриоз: влияние гормональных, иммунологических и генетических факторов на развитие, особенности течения и выбор терапии: Автореф.дис… д-ра мед.наук. — СПб., 2009. — 40 с.

[6]	Bulun S. E. Endometriosis: mechanisms of disease // The New England Journal of Medicine. — 2009. — Vol. 360, N 3. — P. 268–279.

[7]	Estrogen production in endometriosis and use of aromatase inhibitors to treat endometriosis / S. E. Bulun [et al.] // Endocrine-Related Cancer. — 1999. — Vol. 6, N 2. — P. 293–301.

[8]	Guidice L. C., Evers J. L. H., Healy D. L. Endometriosis: science and practice. — N. Y.: John Wiley Sons, 2012. — 600 p.

[9]	Guo S. W. Recurrence of endometriosis and its control // Hum. Reprod. — 2009. — Vol. 15, N 4. — P. 441–461.

[10]	Sampson J. A. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity //Am. J. Obstet. Gynecol. — 1927. — Vol. 14. — P. 422.